Published in J Clin Endocrinol Metab on October 10, 2006
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. J Endocrinol Invest (2015) 1.98
A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2009) 1.60
Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg (2011) 1.49
Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg (2010) 1.32
Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One (2008) 1.10
Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin Med Res (2007) 1.07
Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol (2011) 1.07
Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci Transl Med (2014) 1.00
Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma. Nucl Med Mol Imaging (2014) 0.91
The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients. Eur J Nucl Med Mol Imaging (2011) 0.89
Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications. J Cancer (2013) 0.85
Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection. World J Surg (2012) 0.85
Thyroid cancer: successful remnant ablation-what is success? Nat Rev Endocrinol (2012) 0.79
Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer. J Korean Med Sci (2015) 0.79
Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study. PLoS One (2015) 0.77
Codon-optimized human sodium iodide symporter (opt-hNIS) as a sensitive reporter and efficient therapeutic gene. Theranostics (2015) 0.76
Low versus high I-131 dose for remnant ablation in differentiated thyroid cancer. Clin Med Res (2009) 0.76
Radioiodine Remnant Ablation: A Critical Review. World J Nucl Med (2015) 0.75
I-131 for Remnant Ablation in Differentiated Thyroid Cancer After Thyroidectomy: A Meta-Analysis of Randomized Controlled Evidence. Med Sci Monit (2016) 0.75
Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer. Asia Ocean J Nucl Med Biol (2013) 0.75
Use of Pre-Ablation Radioiodine-131 Scan to Assess the Impact of Surgical Volume and Specialisation following Thyroidectomy for Differentiated Thyroid Carcinoma. Eur Thyroid J (2013) 0.75
The role of nuclear medicine in differentiated thyroid cancer. Wien Med Wochenschr (2012) 0.75
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA (2004) 8.12
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
Iodine status of UK schoolgirls: a cross-sectional survey. Lancet (2011) 4.96
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes (2004) 4.81
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med (2012) 4.59
Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med (2010) 3.24
Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf) (2007) 3.17
Iodine supplementation for pregnancy and lactation-United States and Canada: recommendations of the American Thyroid Association. Thyroid (2006) 2.56
Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med (2012) 2.24
Parameters for reliable results in genetic association studies in common disease. Nat Genet (2002) 2.00
A single nucleotide polymorphism in the CD40 gene on chromosome 20q (GD-2) provides no evidence for susceptibility to Graves' disease in UK Caucasians. Clin Endocrinol (Oxf) (2004) 1.64
A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2009) 1.60
Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol (2006) 1.59
Seven newly identified loci for autoimmune thyroid disease. Hum Mol Genet (2012) 1.57
Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf) (2002) 1.53
Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur J Hum Genet (2005) 1.49
Regression mapping of association between the human leukocyte antigen region and Graves disease. Am J Hum Genet (2004) 1.47
Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol (2005) 1.46
Childhood weight gain and thyroid autoimmunity at age 60-64 years: the 1946 British birth cohort study. J Clin Endocrinol Metab (2013) 1.45
A comparative quality assessment of evidence-based clinical guidelines in endocrinology. Clin Endocrinol (Oxf) (2013) 1.42
Cardiovascular abnormalities in hyperthyroidism. Am J Med (2005) 1.38
Thyroid cancer causing obstruction of the great veins in the neck. World J Surg Oncol (2008) 1.35
A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effect. Hum Mol Genet (2007) 1.35
Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly: a community-based cross-sectional survey. J Clin Endocrinol Metab (2006) 1.30
Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum Mol Genet (2009) 1.26
Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene (2005) 1.14
A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci (2009) 1.06
Long-term results in elderly patients with differentiated thyroid carcinoma. Cancer (2003) 1.06
Association of PTPN22 haplotypes with Graves' disease. J Clin Endocrinol Metab (2006) 1.05
Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Res (2010) 1.02
Management of thyroid cancer. Lancet Oncol (2002) 1.01
Pituitary tumor-transforming gene and its binding factor in endocrine cancer. Expert Rev Mol Med (2010) 1.01
Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. J Clin Endocrinol Metab (2014) 1.00
Polymorphism of the CTLA-4 gene is associated with autoimmune hypothyroidism in the United Kingdom. Thyroid (2002) 0.98
Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. Radiother Oncol (2007) 0.98
Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. J Clin Endocrinol Metab (2005) 0.98
Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid (2002) 0.95
Early expression of thyroid hormone deiodinases and receptors in human fetal cerebral cortex. Brain Res Dev Brain Res (2002) 0.92
The relationship between serum TSH and free T4 in older people. J Clin Pathol (2012) 0.92
Expression and function of the novel proto-oncogene PBF in thyroid cancer: a new target for augmenting radioiodine uptake. J Endocrinol (2011) 0.91
Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts. PLoS One (2010) 0.90
Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. Cancer Res (2011) 0.90
Patient information in Graves' disease and thyroid-associated ophthalmopathy: readability assessment of online resources. Thyroid (2013) 0.88
Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer. Thyroid (2006) 0.87
Skewed X chromosome inactivation and female preponderance in autoimmune thyroid disease: an association study and meta-analysis. J Clin Endocrinol Metab (2013) 0.86
Confirmation of association of chromosome 5q31-33 with United Kingdom Caucasian Graves' disease. Thyroid (2010) 0.86
Prolonged survival due to spontaneous regression and surgical excision of malignant mesothelioma. Ann Thorac Surg (2007) 0.85
Placental transport of thyroid hormone. Best Pract Res Clin Endocrinol Metab (2007) 0.85
Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys (2009) 0.85
Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer. J Clin Endocrinol Metab (2013) 0.84
Successful treatment of amiodarone-induced thyrotoxicosis. Circulation (2002) 0.84
Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. Carcinogenesis (2003) 0.84
The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. Endocrinology (2014) 0.84
Levothyroxine treatment and occurrence of fracture of the hip. Arch Intern Med (2002) 0.83
MCT8 expression in human fetal cerebral cortex is reduced in severe intrauterine growth restriction. J Endocrinol (2014) 0.83
Follow-up of potential novel Graves' disease susceptibility loci, identified in the UK WTCCC genome-wide nonsynonymous SNP study. Eur J Hum Genet (2010) 0.83
Association of Fc receptor-like 5 (FCRL5) with Graves' disease is secondary to the effect of FCRL3. Clin Endocrinol (Oxf) (2010) 0.83
Thyroid cancer: an overview. Nucl Med Commun (2004) 0.83
Radioiodine treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab (2003) 0.82
The effects of acute triiodothyronine therapy on myocardial gene expression in brain stem dead cardiac donors. J Clin Endocrinol Metab (2010) 0.82
Heart rate variability and turbulence in hyperthyroidism before, during, and after treatment. Am J Cardiol (2004) 0.82
Regulation of pituitary tumor transforming gene (PTTG) expression and phosphorylation in thyroid cells. Endocrinology (2013) 0.82
Monocarboxylate transporter 8 modulates the viability and invasive capacity of human placental cells and fetoplacental growth in mice. PLoS One (2013) 0.81
Role and regulation of the fibroblast growth factor axis in human thyroid follicular cells. Am J Physiol Endocrinol Metab (2003) 0.80
A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves' disease: Comment on the article by Rood et al. Arthritis Rheum (2002) 0.80
Association of FcGRIIa with Graves' disease: a potential role for dysregulated autoantibody clearance in disease onset/progression. Clin Endocrinol (Oxf) (2010) 0.80
Impact of month of birth on the development of autoimmune thyroid disease in the United Kingdom and Europe. J Clin Endocrinol Metab (2014) 0.79
Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace? J Clin Endocrinol Metab (2002) 0.79
A patient with asymmetric parotid uptake on a diagnostic iodine-131 scan during thyroid cancer follow-up. Thyroid (2007) 0.79
How does glucose insulin potassium improve hemodynamic performance? Evidence for altered expression of beta-adrenoreceptor and calcium handling genes. Circulation (2006) 0.79
Polymorphisms of interleukin 4 receptor gene and interleukin 10 gene are not associated with Graves' disease in the UK. Autoimmunity (2004) 0.78
Maternal nutrient deprivation induces sex-specific changes in thyroid hormone receptor and deiodinase expression in the fetal guinea pig brain. J Physiol (2005) 0.78
Thyroid gland: Antithyroid therapy--best choice of drug and dose. Nat Rev Endocrinol (2009) 0.78
Transcriptional regulation of the human glycoprotein hormone common alpha subunit gene by cAMP-response-element-binding protein (CREB)-binding protein (CBP)/p300 and p53. Biochem J (2002) 0.78
Low versus high I-131 dose for remnant ablation in differentiated thyroid cancer. Clin Med Res (2009) 0.76
Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab (2013) 0.76
Well-being after radiation therapy in thyroid cancer. N Engl J Med (2013) 0.75
Thyroid function tests and hypothyroidism. Restoring serum TSH to reference range should be goal of replacement. BMJ (2003) 0.75
Is radioiodine good for hyperthyroidism? Nat Clin Pract Endocrinol Metab (2008) 0.75
Inpatient management of diabetes in adults: safety and good practice. Br J Hosp Med (Lond) (2014) 0.75
The relationship between serum TSH and free T4 in older people. Postgrad Med J (2012) 0.75
Idiopathic aqueductal stenosis. Clin Med (2012) 0.75
Metastatic thyroid carcinoma causing superior vena caval obstruction diagnosed on I-131 scan. Clin Nucl Med (2005) 0.75
Adenovirus-mediated expression of dominant negative fibroblast growth factor (FGF) receptor 1 in thyroid cells blocks FGF effects and reduces goitrogenesis in mice. J Clin Endocrinol Metab (2003) 0.75
Diagnostic 131I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer. Eur J Endocrinol (2004) 0.75
Medullary and non-medullary thyroid cancer in a family. Acta Oncol (2004) 0.75